---
title: "Intuitive Surgical Revenue Surges as Health Tech and Frontier Services Scale Commercial Operations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296894342.md"
description: "Hardware and software providers are aggressively scaling in 2026. Intuitive Surgical delivered an 18.4% revenue jump, Veeva locked in Eli Lilly for its CRM platform, and Joby Aviation boosted its full-year guidance following major defense acquisitions."
datetime: "2026-08-25T10:11:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296894342.md)
  - [en](https://longbridge.com/en/news/296894342.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296894342.md)
generator: "portal-rs"
---

# Intuitive Surgical Revenue Surges as Health Tech and Frontier Services Scale Commercial Operations

The intersection of advanced medical hardware, life sciences software, and frontier mobility is seeing a massive deployment of capital and revenue realization in the second half of 2026. Intuitive Surgical (ISRG.US) continues to command the robotic-assisted surgery market with robust second-quarter metrics, reporting a revenue jump of 18.4% to USD 2.89 billion. The medical device manufacturer is rapidly expanding its global manufacturing footprint with a new facility in Penang, Malaysia, to support the rollout of its software-centric da Vinci 5 platform.

In the enterprise software ecosystem, Veeva Systems (VEEV.US) is tightening its grip on top-tier pharmaceutical clients. The cloud provider scored a major commercial victory in August when Eli Lilly selected its Vault CRM system. Coupled with its strategic acquisition of Copli and the rollout of regulatory-focused AI Agents, Veeva is positioning itself as the indispensable digital backbone for global drug development and commercialization.

Niche biopharma players are securing their operational moats by clearing legal hurdles. Aurinia Pharmaceuticals (AUPH.US) posted USD 37.4 million in second-quarter net income while holding onto USD 443.1 million in cash. More critically, the firm struck a patent settlement with generic giant Teva in August, effectively shielding its lupus nephritis therapy LUPKYNIS from U.S. generic competition until at least 2036.

Meanwhile, Joby Aviation (JOBY.US) is aggressively leveraging M&A and capital markets to fund its commercial air taxi ambitions. The eVTOL developer delivered a second-quarter top-line beat of USD 38.6 million and subsequently raised its full-year 2026 revenue guidance to a range of USD 115 million to USD 125 million. Backed by a newly filed USD 750 million equity offering and the acquisition of defense technology firm Resonant Sciences, Joby is laying the groundwork for a dual-use infrastructure network targeting both commercial transport and defense contracts.

### Related Stocks

- [ISRG.US](https://longbridge.com/en/quote/ISRG.US.md)
- [VEEV.US](https://longbridge.com/en/quote/VEEV.US.md)
- [AUPH.US](https://longbridge.com/en/quote/AUPH.US.md)
- [JOBY.US](https://longbridge.com/en/quote/JOBY.US.md)

## Related News & Research

- [Defender Capital LLC. Boosts Stake in Intuitive Surgical, Inc. $ISRG](https://longbridge.com/en/news/300735252.md)
- [Insider Selling: Joby Aviation (NYSE:JOBY) CFO Sells $15,475.95 in Stock](https://longbridge.com/en/news/300969057.md)
- [Air taxi maker Joby Aero owes $116.9 million in trade secrets case, US jury says](https://longbridge.com/en/news/300965878.md)
- [Joby Aviation (JOBY) Nears FAA Certification After Flight Progress While Valuation Questions Build](https://longbridge.com/en/news/300872155.md)
- [Joby lifts outlook as Texas test flights near, Dubai launch in sight](https://longbridge.com/en/news/300838159.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**